下载 Oncology Nursing Drug Handbook - v3.5.13

请下载并共享Oncology Nursing Drug Handbook - v3.5.13，它是类别医疗中的特色应用之一。
另外，还有一些其他应用可以作为Dexcom G6, Pacify, X-RAY WOW, MCQ Abubakr (ASU), Medical PG, FMGE Preparation - PrepLadder, iDentist Dental practice management下载。如果您对Oncology Nursing Drug Handbook - v3.5.13感到满意。

Oncology Nursing Drug Handbook - v3.5.13发布，Oncology Nursing Drug Handbook - v3.5.13是当今最好的免费和最佳手机应用程序之一。位于应用商店的医疗类别中。

Oncology Nursing Drug Handbook - v3.5.13的最低操作系统为Android 5.0+及更高版本。因此，如果尚未升级手机，则必须更新。

在APKDroid上，您将免费下载Oncology Nursing Drug Handbook - v3.5.13 APK，最新版本为3.5.13，发布日期为2020-06-25，文件大小为8.4 MB。根据Google Play商店的统计数据，大约有1000次下载。您可以根据需要更新在Android上单独下载或安装的应用。还可以更新您的应用。您可以使用最新功能并提高安全性和应用程序的稳定性。现在就享受它

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

DESCRIPTION
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

- Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
- Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
- Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
- New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)

Faster download with slow internet connectivity